AU2008282215B2 - Systems and methods for particle radiation enhanced delivery of therapy - Google Patents
Systems and methods for particle radiation enhanced delivery of therapy Download PDFInfo
- Publication number
- AU2008282215B2 AU2008282215B2 AU2008282215A AU2008282215A AU2008282215B2 AU 2008282215 B2 AU2008282215 B2 AU 2008282215B2 AU 2008282215 A AU2008282215 A AU 2008282215A AU 2008282215 A AU2008282215 A AU 2008282215A AU 2008282215 B2 AU2008282215 B2 AU 2008282215B2
- Authority
- AU
- Australia
- Prior art keywords
- agent
- target tissue
- therapeutic agent
- patient
- particle radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000005855 radiation Effects 0.000 title claims abstract description 107
- 239000002245 particle Substances 0.000 title claims abstract description 82
- 238000000034 method Methods 0.000 title claims abstract description 53
- 238000002560 therapeutic procedure Methods 0.000 title claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 82
- 238000003384 imaging method Methods 0.000 claims abstract description 30
- 239000002086 nanomaterial Substances 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 28
- 238000001727 in vivo Methods 0.000 claims abstract description 25
- 239000002105 nanoparticle Substances 0.000 claims abstract description 22
- 230000009471 action Effects 0.000 claims abstract description 7
- 239000002539 nanocarrier Substances 0.000 claims abstract 6
- 239000003814 drug Substances 0.000 claims description 78
- 229940124597 therapeutic agent Drugs 0.000 claims description 72
- 239000003981 vehicle Substances 0.000 claims description 42
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 239000003223 protective agent Substances 0.000 claims description 33
- 239000000969 carrier Substances 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- 230000009286 beneficial effect Effects 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000000354 decomposition reaction Methods 0.000 claims 3
- 238000012886 linear function Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 12
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 3
- 230000008713 feedback mechanism Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 83
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 239000003560 cancer drug Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 238000013459 approach Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 229940039231 contrast media Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002661 proton therapy Methods 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229910021417 amorphous silicon Inorganic materials 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229950001178 capromab Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 238000002786 image-guided radiation therapy Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 238000002727 particle therapy Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002534 radiation-sensitizing agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
- A61N2005/1087—Ions; Protons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95277307P | 2007-07-30 | 2007-07-30 | |
| US60/952,773 | 2007-07-30 | ||
| PCT/US2008/071653 WO2009018383A1 (en) | 2007-07-30 | 2008-07-30 | Systems and methods for particle radiation enhanced delivery of therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008282215A1 AU2008282215A1 (en) | 2009-02-05 |
| AU2008282215B2 true AU2008282215B2 (en) | 2014-05-29 |
Family
ID=40304856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008282215A Ceased AU2008282215B2 (en) | 2007-07-30 | 2008-07-30 | Systems and methods for particle radiation enhanced delivery of therapy |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2173430A4 (https=) |
| JP (1) | JP5331116B2 (https=) |
| AU (1) | AU2008282215B2 (https=) |
| CA (1) | CA2695985C (https=) |
| WO (1) | WO2009018383A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3136594B2 (ja) | 1990-02-28 | 2001-02-19 | ソニー株式会社 | 非水電解液二次電池 |
| US8669533B2 (en) | 2009-10-01 | 2014-03-11 | Vladimir Bashkirov | Ion induced impact ionization detector and uses thereof |
| JP2023512214A (ja) | 2020-01-28 | 2023-03-24 | リフレクション メディカル， インコーポレイテッド | 放射性核種および外部ビーム放射線療法の共同最適化 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030228260A1 (en) * | 1990-09-14 | 2003-12-11 | Syngenix Limited | Particulate agents |
| US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| US20050276861A1 (en) * | 2004-06-15 | 2005-12-15 | Kipp James E | Ex-vivo application of solid microparticulate therapeutic agents |
| US20070009441A1 (en) * | 2004-07-08 | 2007-01-11 | Molecular Therapeutics, Inc. | Biodegradable nanoparticles |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
| US4917344A (en) | 1988-04-07 | 1990-04-17 | Loma Linda University Medical Center | Roller-supported, modular, isocentric gantry and method of assembly |
| US5117829A (en) | 1989-03-31 | 1992-06-02 | Loma Linda University Medical Center | Patient alignment system and procedure for radiation treatment |
| US5825845A (en) | 1996-10-28 | 1998-10-20 | Loma Linda University Medical Center | Proton beam digital imaging system |
| US6645464B1 (en) * | 1998-07-30 | 2003-11-11 | James F. Hainfeld | Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy |
| US6159443A (en) * | 1999-04-29 | 2000-12-12 | Vanderbilt University | X-ray guided drug delivery |
-
2008
- 2008-07-30 CA CA2695985A patent/CA2695985C/en active Active
- 2008-07-30 WO PCT/US2008/071653 patent/WO2009018383A1/en not_active Ceased
- 2008-07-30 EP EP08826721A patent/EP2173430A4/en not_active Withdrawn
- 2008-07-30 JP JP2010520162A patent/JP5331116B2/ja not_active Expired - Fee Related
- 2008-07-30 AU AU2008282215A patent/AU2008282215B2/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030228260A1 (en) * | 1990-09-14 | 2003-12-11 | Syngenix Limited | Particulate agents |
| US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| US20050276861A1 (en) * | 2004-06-15 | 2005-12-15 | Kipp James E | Ex-vivo application of solid microparticulate therapeutic agents |
| US20070009441A1 (en) * | 2004-07-08 | 2007-01-11 | Molecular Therapeutics, Inc. | Biodegradable nanoparticles |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2695985A1 (en) | 2009-02-05 |
| AU2008282215A1 (en) | 2009-02-05 |
| JP5331116B2 (ja) | 2013-10-30 |
| EP2173430A1 (en) | 2010-04-14 |
| JP2010535084A (ja) | 2010-11-18 |
| CA2695985C (en) | 2016-06-28 |
| WO2009018383A1 (en) | 2009-02-05 |
| EP2173430A4 (en) | 2012-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chua et al. | Emerging technologies for local cancer treatment | |
| Chen et al. | Gold nanoparticles as radiosensitizers in cancer radiotherapy | |
| Boateng et al. | Delivery of nanoparticle-based radiosensitizers for radiotherapy applications | |
| US20150050349A1 (en) | Systems and methods for particle radiation enhanced delivery of therapy | |
| Babu et al. | Nanoparticle‐based drug delivery for therapy of lung cancer: progress and challenges | |
| Bilynsky et al. | Radiation nanosensitizers in cancer therapy—From preclinical discoveries to the outcomes of early clinical trials | |
| US10413755B1 (en) | Device and methods for adaptive resistance inhibiting proton and carbon ion microbeams and nanobeams radiosurgery | |
| Lee et al. | Smart nanoparticles for drug delivery: Boundaries and opportunities | |
| Chatterjee et al. | Convergence of nanotechnology with radiation therapy—insights and implications for clinical translation | |
| Eblan et al. | Improving chemoradiotherapy with nanoparticle therapeutics | |
| AU2008282215B2 (en) | Systems and methods for particle radiation enhanced delivery of therapy | |
| JP6905051B2 (ja) | イオン注入により形成された中性子捕捉療法用の組成物 | |
| US20170173364A1 (en) | Nanoparticle-mediated ablation of glioblastoma and of other malignancies | |
| Edward Werner et al. | Chemoradiotherapy of human tumors: novel approaches from nanomedicine | |
| EP3180085B1 (en) | Means and methods for targeted x-ray therapy | |
| Pavanalaxmi et al. | Implementation of biomedical engineering tools in targeted cancer therapy: challenges and opportunities | |
| Sengupta et al. | Ultrasound‐Mediated Nanocarrier‐Based Drug Delivery in Breast Cancer Therapy: Innovations and Outlook | |
| TSOURKAS | Developing targeted theranostic nanoparticles: challenges and potential solutions | |
| Sahil et al. | Enhanced Urease-Driven Nanobots for Radionuclide-Based Bladder Cancer Therapy | |
| Pingali | Therapy: Challenges and Opportunities | |
| Zaheer | Cancer Nanomedicines in the Clinic: Coming of Age | |
| Sahoo et al. | Smart Nano-Carriers and Their Advancements | |
| Qadrie et al. | Exploring the Role OF Targeted Drug Delivery in Enhancing Cancer Treatment Outcomes | |
| Khalaji et al. | Recent developments in nanoparticle-enhanced radiotherapy for breast cancer treatment | |
| Tng et al. | Nanoparticles for Enhanced Radiotherapy and Imaging Applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |